Plain-English translation of NCT06726889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Many people with metastatic breast cancer are prescribed oral anticancer medications—pills or tablets taken by mouth instead of intravenous infusions. While patients often prefer this form, many struggle to take them as directed. This study is testing different combinations of support tools—like educational materials, reminder messages, and personalized feedback from your doctor—to help you stick with your medication schedule.
Even though oral cancer medications can be convenient and flexible, research shows that many patients don't take them consistently, which can affect how well the treatment works. Most previous studies focused on other types of breast cancer patients, so researchers want to find the best ways to support people taking this medication for advanced disease.
You likely qualify if…
You likely don't qualify if…
You'll be randomly assigned to receive one of eight different support packages alongside your regular cancer care. Some groups will receive educational materials through a website, others will get personalized reminder messages on their phone, some will receive feedback from their doctor about how well they're taking their medication, or combinations of these tools. You'll continue taking your prescribed oral medication and visit your clinic for scheduled appointments to help researchers see which combination of support tools works best.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy
Sponsor
European Institute of Oncology
Enrollment target
~104 participants
Started
January 2024
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gabriella Pravettoni, MD
European Istitute of Oncology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.